Anti-IFNAR2 Antibody (FITC)

1/2
Price:
Size:
Number:

Anti-IFNAR2 Antibody (FITC) (Mouse Monoclonal antibody) General Information

Product name
Anti-IFNAR2 Antibody (FITC)
Validated applications
FCM
Species reactivity
Reacts with: Human
Specificity
Human IFNAR2
Immunogen
Recombinant Human IFNAR2 protein (Catalog#10359-H08H)
Preparation
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human IFNAR2 (rh IFNAR2; Catalog#10359-H08H; NP_997468.1; Met 1-Lys 243) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.
Source
Monoclonal Mouse IgG1 Clone #07
Purification
Protein A
Formulation
Aqueous solution containing 0.5% BSA and 0.09% sodium azide
Conjugate
FITC
Concentration
10 μl/Test, 0.1 mg/ml
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for twelve months without detectable loss of activity. Protected from prolonged exposure to light. Do not freeze ! Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

Anti-IFNAR2 Antibody (FITC) (Mouse Monoclonal antibody) Images

Profile of anti-IFNAR2 reactivity on KG-1 cells analyzed by flow cytometry.
Profile of anti-IFNAR2 reactivity on Jurkat cells analyzed by flow cytometry.

Anti-IFNAR2 Antibody (FITC): Alternative Names

Anti-IFN-alpha-REC Antibody; Anti-IFN-R Antibody; Anti-IFNABR Antibody; Anti-IFNARB Antibody

IFNAR2 Background Information

Interferon-alpha/beta receptor beta chain (IFNAR2) is a type I membrane protein that forms one of the two chains of a receptor for interferons alpha and beta. Binding and activation of the receptor stimulates Janus protein kinases, which in turn phosphorylate several proteins, including STAT1 and STAT2. Initial cell-surface IFNAR2 expression at diagnosis assessed by flow cytometry widely distributed but showed overall significantly higher expression in CML patients when compared with normal controls. In 15 fresh patients who subsequently received IFNα therapy, IFNAR2 expression at diagnosis was significantly higher in cytogenetic good responders than in poor responders. Down-regulation of IFNAR2 expression during IFNα therapy was observed only in good responders but not in poor responders. The encoded protein also functions as an antiviral factor. IFNAR2 may associate with IFNAR1 to form the type I interferon receptor. This protein serves as a receptor for interferons alpha and beta. IFNAR2 is also involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity. Following binding of IFNα2, IFNAR2 is internalized, but, instead of being routed towards degradation as it is when complexed to IFNβ, it recycles back to the cell surface.
Full Name
interferon (alpha, beta and omega) receptor 2
References
  • Ito K, et al. (2004) Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia. Eur J Haematol. 73(3): 191-205.
  • Kim SH, et al. (1997) Mammalian type I interferon receptors consists of two subunits: IFNaR1 and IFNaR2. Gene. 196(1-2): 279-86.
  • Saleh AZ, et al. (2004) Regulated proteolysis of the IFNaR2 subunit of the interferon-alpha receptor. Oncogene. 23(42): 7076-86.
  • STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling
    Author
    Arimoto, KI;Löchte, S;Stoner, SA;Burkart, C;Zhang, Y;Miyauchi, S;Wilmes, S;Fan, JB;Heinisch, JJ;Li, Z;Yan, M;Pellegrini, S;Colland, F;Piehler, J;Zhang, DE;
    Year
    2017
    Journal
    Nat. Struct. Mol. Biol
    Application
    FAC
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait